Why drugmakers are so enamored of rare-disease meds

One of the big trends in drug development over the past three years has been the growing popularity of new treatments for rare diseases. And if you read through Bloomberg's lengthy feature on Novato, CA-based BioMarin's program for achondroplasia--a rare bone growth disorder that causes dwarfism--you'll see why. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.